Readership Survey Charts V2 150ppi 1

GPs vote AusDoc #1 in Print, Online & Newsletters

GP Readership Survey of Independent Australian Medical Publications (November 2023) A survey of more than 330 Australian GPs has once again confirmed the reach and influence of independent medical publications as being critically important for any organisation looking to communicate with doctors1.    The survey run by AusDoc was shared with 26,000 AHPRA verified GPs, with more

View

Healthcare Marketing - right content type for your campaign

5 ways to choose the right content type for your campaign

Have you ever wondered which type of content will work best for your campaign? If so, you’re not alone. It’s one of the most frequently asked questions AusDoc receives from marketers and agencies. The key to success is to think like a journalist, says Amanda Davey, AusDoc Commercial Content Editor and the former editor of

View

Growth Frequency 03

How increasing message frequency led to a +14% growth in prescribing

Whether it be the original ‘Rule of 7’or more recent studies that suggest the new number is much higher in the digital age we now live in, the premise remains that increasing message frequency can have a significant impact on retention and driving behaviour change, but does this theory extend to doctors? Let’s start with

View

Rsz Ih Solus Edm

How a solus eDM helped a pharma brand to quickly regain lost market share following negative publicity

A leading prescription brand had lost market share following negative publicity. With local key opinion leaders questioning the brand’s efficacy, both medical and consumer media were running hard with the story – eroding prescriber and patient trust. The client needed a powerful tool to support its omnichannel response and quickly turn this around.

View

Rsz Mc Article 1

Exclusive AusDoc survey: Understanding doctors’ perceptions and behaviours regarding medicinal cannabis 

Exclusive AusDoc survey. What you will learn from reading this article:   Doctors are experiencing increased patient demand for medicinal cannabis, but most acknowledge a lack of knowledge about risks and benefits and are unsure how to advise patients, says a 2021 meta-analysis of 21 international articles. Fast-forward to 2023 and not much has changed, according

View

Rsz Mc Article 2

How a lack of brand awareness is creating an opportunity for medicinal cannabis marketers

Exclusive AusDoc survey. What you will learn from reading this article: Doctors have little knowledge of medicinal cannabis brands, according to the results of an AusDoc survey involving more than 240 GPs and specialists across Australia. In a finding that leaves space wide open for marketers to build their brand equity, 77% of survey respondents

View

Rsz Omnichannel Strategy

Is your Medical Affairs engagement strategy ready for an omnichannel future?

Medical Affairs professionals must demonstrate digital competency and mindset change to continue benefiting from the Covid-19 digital transformation, according to an opinion article by Daniel Furtner and colleagues. They write that engagement of the future will need to be high quality and tailored to individual doctors’ needs and preferences. And digital tools will replace many

View

Rsz Print Qr Code

How print adverts can add smarts and oomph to your digital campaign 

The large canvas offered by print makes it the billboard of S4 marketing. And that billboard is becoming increasingly dynamic, thanks to the ubiquitous QR code. Print advertising has ridden the wave of digital disruption to remain an integral part of the pharmaceutical omnichannel marketing mix.  “Clever marketers are using print in a different way.

View

Inside Healthcare April 2023 New Products

How do busy GPs want to find out about new medications?  

With the TGA registering an average of three new medicines a month and the PBS updating its schedule several times a year, we explored how GPs prefer to find out about new medicines.  According to one study, GPs are unlikely to spontaneously go looking for information about new medicines. Instead, they are described as reactive

View